Eris Lifesciences acquired a 100% stake in subsidiary Eris Pharmaceuticals

January 25, 2007, saw the incorporation of Eris Lifesciences Limited. Later, on February 9, 2007, the company was renamed ‘Eris Lifesciences Private Limited’. Additionally, on February 2, 2017, the business changed its name to ‘Eris Lifesciences Limited’ and became a public limited company. The company currently manufactures and markets pharmaceutical products from its manufacturing facility in Guwahati, Assam. It is present in acute, chronic, and subchronic therapeutic areas with high growth rates that call for a high level of specialist and superspecialty physician intervention. In addition, it boasts a portfolio of 112 Mother Brands in various therapeutic domains. The company develops, manufactures, and distributes branded pharmaceutical products in the chronic and acute segments of the Indian Pharmaceutical Market (IPM) that target particular therapeutic areas, such as cardiovascular, anti-diabetic, vitamin, gastroenterology, and anti-infective.

100% ownership of Eris Pharmaceuticals by Eris Lifesciences

Eris Lifesciences will be able to fortify its product line and increase its footprint in the pharmaceutical sector thanks to this acquisition. The business will have complete operational control over the subsidiary and be able to use Eris Pharmaceuticals’ resources and experience to spur innovation and growth if it purchases a 100% share in the business. This calculated action shows Eris Lifesciences’ dedication to making investments in the future and securing its place as a major force in the healthcare industry.

Further details about Eris Lifesciences

The public owns 45.13% of Eris Lifesciences. On September 30, 2024, the mutual fund holding in Eris Lifesciences was at 0.92%. The MF holding has grown since the previous quarter. On September 30, 2024, the FII’s stake in Eris Lifesciences was 8.01%. The FII holding has grown since the previous quarter.

Today, Eris Lifesciences Ltd.’s stock is up 1%

Eris Lifesciences Ltd.’s stock was once trading at Rs. 1,303.20 per share, but it is now trading at Rs. 1,289.35 per share. This suggests that the stock is trending upward and will probably keep rising.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.